-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 11, 2021 , the World Health Organization (WHO) Strategic Advisory Expert Group (SAGE) of the World Health Organization (WHO), after four days of talks, gave the first recommendations for people who need to be "enhanced vaccination" , and made specific recommendations for Chinese vaccines.
On October 11, 2021, it is the first time to give advice to people who need to "enhance vaccination"
Among the key points of the resolution given by SAGE, there are three opinions concerning COVID-19, in order:
1.
1
2.
2 moderate to severe immunocompromised people additional vaccination
3.
3 Inoculated with Kexing or Sinopharm inactivated vaccine, and an additional third dose of homologous and heterologous vaccine for people 60 years and older
Among them, the second and third points are worthy of attention
First of all, this is the first time that the WHO has proposed an "enhanced shot" vaccination program for COVID-19
First of all, this is the first time that the WHO has proposed an "enhanced shot" vaccination program for COVID-19
The initial vaccination program (pri mary series) booster (booster)
Additional dose (extended primary series) booster
On the second day after the announcement of this resolution, WHO Director-General Dr.
"Immoral, unfair and unjust and it has to stop,"
"Immoral, unfair, and unethical, we must stop
The WHO's recommendation of universal vaccination is definitely morally correct, but the actual implementation and the use of booster needles in various countries are indeed due to the needs of the epidemic
(Pandemic changes)
Secondly, this SAGE resolution also made special instructions for Chinese vaccines
Secondly, this SAGE resolution also made special instructions for Chinese vaccines
WHO recommends that elderly people aged 60 and above who have been vaccinated in China should receive an additional dose of the vaccine, and they also provide options for heterologous vaccination (different types of vaccines)
In fact, this is also one of the three key populations recommended by Chinese experts to strengthen vaccination , namely
Three types of key populations recommended by Chinese experts to strengthen vaccination1) The import risk is high, such as customs, border inspection, aviation, isolation points, designated medical institutions and other staff;
2) People with relatively low immune function, and people over 60 years old;
3) Due to the needs of work, study, and communication, people from overseas high-risk areas or countries
At the 2nd Global Science, Life and Health Parallel Forum on September 25, Yin Zundong, director of the China CDC Immunization Center, said that these three key groups can be boosted 6 months after completing the immunization program
Booster vaccination can be carried out 6 months after completing the immunization program
What happened, or maybe there is
What data is there,
What data is there,Support the WHO's special requirements for vaccines in China?
Support the WHO's special requirements for vaccines in China?On October 14, 2021, Nature magazine issued a special article titled "China's COVID vaccines have been crucial — now immunity is waning" (China's COVID-19 vaccines have been crucial — now immunity is waning) Out of the analysis
1.
How important is the Chinese vaccine to the global fight against the epidemic?
How important is the Chinese vaccine to the global fight against the epidemic?
The title of this article directly uses "crucial", which is very important
.
Use the data to speak directly
.
A total of 7.
3 billion doses of COVID-19 vaccine have been delivered globally, and China Kexing and Sinopharm Group accounted for nearly half
.
(The number of delivered doses of different vaccines is far ahead of the top four, followed by: Kexing, Pfizer-BioNTech, Sinopharm, and AstraZeneca
.
Source: Nature)
In addition to the mainland of junior high schools, the inactivated COVID-19 vaccines of the Sinopharm Beisheng Institute and Kexing are also widely used all over the world
.
(Countries using Sinopharm Beisheng Institute and Kexing COVID-19 vaccine
.
Source: New York Times Vaccine Tracker)
Among the countries that use Chinese vaccines, Indonesia, Brazil, Pakistan, Turkey and Iran have purchased the most
.
(The main countries purchasing vaccines in China
.
Source: Nature)
China's vaccine is so important, and its protection against COVID-19 has naturally attracted much attention
.
.
2.
Chinese vaccines are also facing the decline of neutralizing antibodies
Chinese vaccines are also facing the decline of neutralizing antibodies
According to public data, the protection of Kexing inactivated vaccine against symptomatic COVID-19 is 51%, and that of the vaccine from the Sinopharm Beisheng Institute is 79%; this protection is the same as the 63 reported by AstraZeneca when it was approved by the WHO.
% Is equivalent, but lower than the protective power of Pfizer and Moderna's mRNA vaccine as high as 90%
.
When other vaccines have reported that the protection against COVID-19 infection has decreased over time, attention to China's vaccines has naturally come
.
.
Nature magazine reviewed and sorted out the changes in the protection of Chinese vaccines
.
In a study of 185 health care workers in Thailand, after the second dose of vaccination, 60% of Kexing vaccine vaccinators had high levels of neutralizing antibodies one month later, while 86% of AstraZeneca vaccines
.
However, by 3 months, the proportion of high-level antibodies among Kexing vaccine recipients dropped to 12%
.
.
However, Ben Cowling, an epidemiologist at the University of Hong Kong, emphasized: The weakening of antibodies does not mean the weakening of immune protection
.
Because the vaccine will not only induce neutralizing antibodies, it will also activate memory B cells and T cells, and these immune cells will have a longer lifespan
.
.
The Hong Kong study also provided evidence for this conclusion.
One month after the two vaccination, compared with Pfizer mRNA vaccine, the antibodies induced by Kexing vaccine were significantly lower, but the T cell response was comparable
.
.
Chile, as one of the main vaccine users in China, provides evidence with real-world data: An analysis of the large-scale vaccinators of Coxing in Chile shows that although Coxing vaccine is significantly less protective against symptomatic COVID-19, But the protection against hospitalization is still very high
.
.
In fact, other vaccines have similar changes
.
3.
Homologous or heterologous booster vaccination?
Homologous or heterologous booster vaccination?
Nature magazine emphasized that because the two inactivated virus vaccines themselves induce low neutralizing antibodies, they have a particularly large impact on the elderly
.
This is also the key reason why the WHO made a special statement about vaccines in China this time
.
This is also the key reason why the WHO made a special statement for the Chinese vaccine this time
.
A large-scale analysis of 1 million people hospitalized with COVID-19 in Brazil shows that for people under 80 years old, Coxing vaccine can provide up to 60% protection, and AstraZeneca vaccine can provide 76% protection; but For the elderly aged 80 and above , the protection of Kexing vaccine against severe illness is only 30% , and the protection against death is 45% ; while the AstraZeneca vaccine is 67% and 85%, respectively
.
The Barrel-Netto and other studies have shown that for the elderly 90 years and older , Kexing vaccine can only provide 33% of the protection against death
.
As a result of these studies, Brazil has started to provide mRNA vaccines or viral vector vaccines as a booster vaccination to elderly people over 70 years old in August
.
In this regard, Barrel-Netto emphasized: It is always better to vaccinate Kexing vaccine than not to vaccinate; however, as the problem of vaccine source is alleviated, it is obviously not very wise to continue to use the vaccine
.
However , a set of data recently released by the Chilean Ministry of Health shows that the continued use of Coxing vaccine as a booster is still effective
.
After the booster vaccination, the protection against COVID-19 has jumped from 56% after the second vaccination to 80%, and the protection against hospitalization has increased from 84% to 87%
.
Chinese scholars are also doing research on heterologous mixed vaccination and found that compared with two doses of Koxing vaccine, one or two doses of Koxing vaccine plus one dose of Cansino adenovirus vaccine can induce higher neutralizing antibodies.
Level
.
summary:
summary: On the whole, the WHO finally verbally loosened the booster vaccination .
Although it still refuses to use the term booster vaccination in order to insist on the so-called "fairness"; in fact, countries decide to boost vaccination based on their epidemic situation and the goals they pursue.
Decided
.
The inactivated virus vaccines of Sinopharm and Kexing , due to the relatively low induced neutralizing antibodies, are less protective against COVID-19 infection than mRNA vaccines, especially among the elderly.
Therefore, WHO requires that these two vaccines be vaccinated.
An elderly person with an inactivated virus vaccine received an additional third dose of vaccine, including a heterologous vaccine
.
For individuals, just as different countries and WHO have different opinions, whether or not to vaccinate booster shots and which booster shots to choose are all related to the starting point
.
If you are pursuing infection prevention , strengthening vaccination, wearing masks, and social isolation are still necessary means; if you are pursuing severe disease prevention , then the current standard vaccination is still sufficient for most people
.
Reference source:
Reference source: Reference source: https://cdn.
who.
int/media/docs/default-source/immunization/sage/2021/october/sage_oct2021_meetinghighlights.
pdf?sfvrsn=3dcae610_11
who.
int/media/docs/default-source/immunization/sage/2021/october/sage_oct2021_meetinghighlights.
pdf?sfvrsn=3dcae610_11
https://